{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-085435","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.799661+00:00","generated_at":"2026-06-04T02:53:26.238039+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Finch Therapeutics audit committee falls to 2 members; Nasdaq grants cure period until Mar 2025","bullets":["Susan Graf resigned from board on March 26, 2024, reducing audit committee to 2 independent directors.","Nasdaq requires audit committee of 3 independent directors; company notified Nasdaq on March 28.","Nasdaq notice received April 2; company has until March 26, 2025 or next annual meeting to regain compliance.","If next annual meeting is before September 23, 2024, cure deadline is September 23, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-085435","json":"https://secwatch.observer/filing/0001193125-24-085435.json","markdown":"https://secwatch.observer/filing/0001193125-24-085435.md","text":"https://secwatch.observer/filing/0001193125-24-085435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000119312524085435/0001193125-24-085435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000119312524085435/d817910d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:53:26.238039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29e3763e21252b1039938847e77d004da383bf53","claim":"Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)).","evidence_excerpt":"April 2, 2024, the Company received a notice from Nasdaq acknowledging the fact that the Company does not meet the requirements of such rules. In accordance with Nasdaq Listing Rule 5605(c)(4) and the Nasdaq notice, to regain compliance with the Nasdaq Listing Rules, the Company has until the earlier of March 26, 2025 or its next annual stockholders meeting (or, if the next annual stockholders meeting is held before September 23, 2024, until September 23, 2024) to regain compliance with the Nasdaq Listing Rules related to audit committee composition. SIGNATURES Pursuant to the requirements of","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000119312524085435/0001193125-24-085435-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"audit committee"},{"label":"Rules","value":"5605(c)(2), 5605(c)(4)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}